BCLI
Price
$1.22
Change
-$0.02 (-1.61%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
12.2M
XTLB
Price
$1.55
Change
+$0.32 (+26.02%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
12.36M
Interact to see
Advertisement

BCLI vs XTLB

Header iconBCLI vs XTLB Comparison
Open Charts BCLI vs XTLBBanner chart's image
Brainstorm Cell Therapeutics
Price$1.22
Change-$0.02 (-1.61%)
Volume$600
Capitalization12.2M
XTL Biopharmaceuticals
Price$1.55
Change+$0.32 (+26.02%)
Volume$400
Capitalization12.36M
BCLI vs XTLB Comparison Chart in %
Loading...
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XTLB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCLI vs. XTLB commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCLI is a Hold and XTLB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (BCLI: $1.24 vs. XTLB: $1.60)
Brand notoriety: BCLI and XTLB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCLI: 25% vs. XTLB: 205%
Market capitalization -- BCLI: $12.2M vs. XTLB: $12.36M
BCLI [@Biotechnology] is valued at $12.2M. XTLB’s [@Biotechnology] market capitalization is $12.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCLI’s FA Score shows that 0 FA rating(s) are green whileXTLB’s FA Score has 0 green FA rating(s).

  • BCLI’s FA Score: 0 green, 5 red.
  • XTLB’s FA Score: 0 green, 5 red.
According to our system of comparison, XTLB is a better buy in the long-term than BCLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCLI’s TA Score shows that 4 TA indicator(s) are bullish while XTLB’s TA Score has 6 bullish TA indicator(s).

  • BCLI’s TA Score: 4 bullish, 4 bearish.
  • XTLB’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, XTLB is a better buy in the short-term than BCLI.

Price Growth

BCLI (@Biotechnology) experienced а +5.98% price change this week, while XTLB (@Biotechnology) price change was +33.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

BCLI is expected to report earnings on May 15, 2025.

XTLB is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XTLB($12.4M) and BCLI($12.2M) have the same market capitalization . XTLB YTD gains are higher at: -21.019 vs. BCLI (-45.374). XTLB has higher annual earnings (EBITDA): 630K vs. BCLI (-12.08M). BCLI has more cash in the bank: 1.64M vs. XTLB (133K). BCLI (0) and XTLB (0) have equivalent revenues.
BCLIXTLBBCLI / XTLB
Capitalization12.2M12.4M98%
EBITDA-12.08M630K-1,917%
Gain YTD-45.374-21.019216%
P/E RatioN/AN/A-
Revenue00-
Total Cash1.64M133K1,236%
Total Debt1.77MN/A-
FUNDAMENTALS RATINGS
BCLI vs XTLB: Fundamental Ratings
BCLI
XTLB
OUTLOOK RATING
1..100
7524
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
46
Fair valued
PROFIT vs RISK RATING
1..100
10092
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
6362
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
1350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XTLB's Valuation (46) in the Biotechnology industry is somewhat better than the same rating for BCLI (88) in the Computer Peripherals industry. This means that XTLB’s stock grew somewhat faster than BCLI’s over the last 12 months.

XTLB's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that XTLB’s stock grew similarly to BCLI’s over the last 12 months.

XTLB's SMR Rating (93) in the Biotechnology industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that XTLB’s stock grew similarly to BCLI’s over the last 12 months.

XTLB's Price Growth Rating (62) in the Biotechnology industry is in the same range as BCLI (63) in the Computer Peripherals industry. This means that XTLB’s stock grew similarly to BCLI’s over the last 12 months.

XTLB's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that XTLB’s stock grew similarly to BCLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCLIXTLB
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 21 days ago
82%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XTLB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMZE10.511.56
+17.43%
Amaze Holdings Inc
MGTX8.370.30
+3.72%
MeiraGTx Holdings plc
ADNT22.540.38
+1.71%
Adient plc
NOK5.10-0.05
-0.97%
Nokia Corp
SKYE4.22-0.13
-2.99%
Skye Bioscience

BCLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCLI has been loosely correlated with VBIZF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BCLI jumps, then VBIZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCLI
1D Price
Change %
BCLI100%
-5.34%
VBIZF - BCLI
35%
Loosely correlated
N/A
ATHE - BCLI
35%
Loosely correlated
-4.87%
BLRX - BCLI
30%
Poorly correlated
+13.76%
XTLB - BCLI
29%
Poorly correlated
+30.08%
EYPT - BCLI
28%
Poorly correlated
+10.15%
More

XTLB and

Correlation & Price change

A.I.dvisor indicates that over the last year, XTLB has been loosely correlated with SER. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if XTLB jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XTLB
1D Price
Change %
XTLB100%
+30.08%
SER - XTLB
59%
Loosely correlated
+7.95%
CLDI - XTLB
28%
Poorly correlated
+108.96%
UNCY - XTLB
28%
Poorly correlated
+8.25%
BCLI - XTLB
27%
Poorly correlated
-5.34%
ANRO - XTLB
27%
Poorly correlated
+3.20%
More